First Bundibugyo Ebola vaccine trial kicks off

Efforts to develop the world’s first vaccine for the Bundibugyo strain of Ebola are gaining traction, even as the Democratic Republic of Congo (DRC) grapples with the largest outbreak of this rare virus strain on record. The World Health Organization (WHO) said ongoing trials could mark a major breakthrough, although definitive results may still take months.

According to WHO data as of August 1, the outbreak had recorded 3,748 cases, including 1,657 deaths and 708 recoveries, underlining the severity of the epidemic. Unlike other Ebola strains for which vaccines already exist, the Bundibugyo variant remains without a proven vaccine, treatment, or preventive intervention, making the current outbreak particularly challenging.

However, global research efforts have accelerated. Clinical trials for a Bundibugyo-specific vaccine candidate began in the United Kingdom on July 24, with a parallel study expected to commence in Canada. These early-stage trials are being conducted on animals, including ferrets and monkeys, with findings to be reviewed before progressing to human testing.

Speaking in Geneva, WHO’s acting lead for research and development, Dr Vasee Moorthy, noted that preparedness efforts had significantly improved compared to previous outbreaks. He explained that research protocols had been developed in advance, enabling scientists to respond more quickly once the outbreak was declared in mid-May.

“Despite ongoing efforts, there are still no proven safe and efficacious treatment, preventive or vaccination options for the Bundibugyo species,” Dr Moorthy said, cautioning that it would take several months before more conclusive findings emerge from the trials.

Meanwhile, clinical trials for potential treatments are also being rolled out in Ituri province, the epicentre of the outbreak. Health experts hope that combining vaccine research with therapeutic trials could improve survival rates and strengthen the overall response to the epidemic.

WHO also revealed that new data has emerged from animal studies on Ervebo, a licensed Ebola vaccine that targets a different strain of the virus. While not specific to Bundibugyo, the findings could provide useful insights into broader Ebola response strategies.

The UN health agency’s technical advisory group met last week to review progress and is expected to issue recommendations in the coming days. These are likely to guide the next phase of research and inform global efforts to contain the outbreak.

As cases continue to rise, health authorities say the accelerated research underscores both the urgency of the crisis and the importance of sustained investment in epidemic preparedness, particularly for less common but equally deadly virus strains.

The post First Bundibugyo Ebola vaccine trial kicks off appeared first on Daily Star.